argenx (ENXTBR:ARGX) shares have climbed steadily over the past month, adding 9% and extending an upward trend seen throughout the past year. Investors may be watching to see if this momentum can continue in light of solid financial performance.

See our latest analysis for argenx.

argenx’s strong stretch continues, with the share price up nearly 30% in the past three months and a year-to-date share price return of over 20%. Momentum seems to be building, and with a 34% total shareholder return over the last year, confidence in the company’s growth story is clearly rising.

If argenx’s momentum sparks your curiosity, now is a great time to widen your view and discover See the full list for free.

But with shares not far below analyst price targets and expectations running high, the key question now is whether argenx remains undervalued or if the market has already priced in this impressive growth trajectory.

With argenx closing at €737.40 and the most-followed narrative assigning a fair value of €749.22, current levels sit just below the latest consensus. This slim gap puts the spotlight on the specific financial drivers that shape the outlook for shares right now.

Successful advancement of a robust pipeline with multiple late-stage trials across diverse autoimmune conditions (e.g., empasiprubart and ARGX-119) enhances the probability of delivering multiple blockbuster therapies, providing visibility into future top-line and earnings expansion that is not fully reflected in the current valuation.

Read the complete narrative.

Want to know what’s fueling this valuation call? The narrative centers on future earnings and margin expansion thanks to pipeline breakthroughs. Find out which pivotal assumptions and aggressive financial targets analysts are rallying behind; rarely does a growth story hinge on this level of execution. Click to see the full narrative that’s driving the fair value higher.

Result: Fair Value of €749.22 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, rising competition and increased pricing pressures could dampen future revenue growth. This may challenge the bullish narrative now driving argenx’s valuation.

Find out about the key risks to this argenx narrative.

Switching to a price-to-earnings perspective, argenx is trading at a ratio of 34x, well above the European Biotechs industry average of 17.1x, yet still below its direct peer group at 67.5x. Notably, the current ratio also sits just under its fair ratio of 35.7x. This suggests valuation risk may be lower if earnings growth meets expectations. With these mixed signals, is the market overconfident or simply ahead of the curve?

See what the numbers say about this price — find out in our valuation breakdown.

If you see the story playing out differently or prefer a fresh look at the numbers, you can easily create your own perspective in just a few minutes, Do it your way

A great starting point for your argenx research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Unlock new opportunities by expanding your search beyond a single stock so you can capitalize on trends that are reshaping the market. The Simply Wall Street Screener provides fast, focused methods to spot quality investments before the wider market does.

Boost your passive income by targeting steady payout leaders through 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 17 dividend stocks with yields > 3% offering yields above 3%.

Join the AI movement and access early opportunities in innovative companies found with these 25 AI penny stocks advancing artificial intelligence technology.

Position yourself for future growth by exploring the rapidly expanding digital asset sector via these 82 cryptocurrency and blockchain stocks fueling the next phase of finance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ARGX.BR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com